Quidel to Hold BNP Supply Agreement Update Conference Call on December 10, 2018
December 07 2018 - 07:31PM
Business Wire
Quidel Corporation (NASDAQ: QDEL), a provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, will hold a conference call on
December 10, 2018 to discuss the San Diego Superior Court’s ruling
related to Quidel’s BNP Supply Agreement with Beckman.
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will host an investment community
conference call beginning at 8:30 a.m. Eastern Time (5:30 a.m.
Pacific Time) on Monday, December 10th to discuss the outcome.
During the conference call, management may answer questions
regarding the intended ruling. Quidel’s responses to these
questions, as well as other matters discussed during the conference
call, may contain or constitute material information that has not
been previously disclosed.
To participate in the live call by telephone from the U.S., dial
877-930-5791, or from outside the U.S., dial 253-336-7286, and
enter the audience pass code 846-3868.
A live webcast of the call can be accessed on the Investor
Relations section of the Quidel website (http://ir.quidel.com). The
website replay will be available for 14 days. The telephone replay
will be available for 48 hours beginning at 10:00 a.m. Eastern Time
(7:00 a.m. Pacific Time) on December 10, 2018 by dialing
855-859-2056 from the U.S., or by dialing 404-537-3406 for
international callers, and entering pass code 846-3868.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being
of people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide
economic benefits to the healthcare system. Marketed under the
Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage® and
InflammaDry® leading brand names, as well as under the new Solana®,
AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s products
aid in the detection and diagnosis of many critical diseases and
conditions, including, among others, influenza, respiratory
syncytial virus, Strep A, herpes, pregnancy, thyroid disease and
fecal occult blood. Quidel's recently acquired Triage® system of
tests comprises a comprehensive test menu that provides rapid,
cost-effective treatment decisions at the point-of-care (POC),
offering a diverse immunoassay menu in a variety of tests to
provide healthcare providers with diagnostic answers for
quantitative BNP, CK-MB, d-dimer, myoglobin, troponin I and
qualitative TOX Drug Screen. Quidel’s research and development
engine is also developing a continuum of diagnostic solutions from
advanced immunoassay to molecular diagnostic tests to further
improve the quality of healthcare in physicians’ offices and
hospital and reference laboratories. For more information about
Quidel’s comprehensive product portfolio, visit quidel.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181207005587/en/
Quidel Contact:Quidel CorporationRandy StewardChief Financial
Officer(858) 552-7931
Media and Investors Contact:Quidel CorporationRuben Argueta(858)
646-8023rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Feb 2024 to Mar 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Mar 2023 to Mar 2024